Comparisons › LLY / NVO
Eli Lilly vs Novo Nordisk: comparing LLY and NVO stock
12-month growth, from 100━ LLY +48.1% ━ NVO −13.8%
| Metric | LLY | NVO |
|---|---|---|
| Price, $ | 1,364.73 | 40.30 |
| Year to date | +27.4% ● | −17.9% |
| 12 months | +48.1% ● | −13.8% |
| From 52-week high | −6.1% ● | −34.9% |
| vs 200-day average | +24.3% ● | −7.2% |
| P/E | 42.7 | 10.5 |
| Dividend yield | 0.49% | 3.20% ● |
| Revenue growth, YoY | +45.5% ● | +5.7% |
| Operating income growth | +70.2% ● | −5.2% |
| Operating margin | 51.2% ● | 43.4% |
| Gross margin | 83.6% ● | 81.1% |
| Market cap | $1.28T | $134.8B |
| Next earnings | Feb 10, 2027 | Feb 3, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: Eli Lilly or Novo Nordisk?
We do not advise what to buy. By the numbers: Eli Lilly rose more over the year (+48.1%); Eli Lilly is closer to its 52-week high; Eli Lilly has the higher operating margin; Eli Lilly is growing revenue faster; Novo Nordisk has the lower P/E. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
Eli Lilly — Feb 10, 2027; Novo Nordisk — Feb 3, 2027.